RESULTS: High LASP1 expression correlated with metastatic recurrence rate between patients. The LASP1 expression is higher in UC1 and T24 cells than in UC13 and UC6 cells. Knockdown of LASP1 using siRNA inhibited cell growth, and was accompanied by an increase in p21 and p27, and a decreased of cyclin D1. Flow cytometry revealed that LASP1 knockdown induced G1 arrest. Conversely, stable LASP1 overexpression drove cell growth with an increase of cyclin D1 in UC6 and UC3 cells. The treatment of CDDP and GEM induced LASP1 expression in Western Blotting. Furthermore, compared with parental cell line, LASP1 is higher in T24 CDDP-R and RT112 CDDP-R cells than in parental cells. LASP1 ASO inhibited cell growth in RT112 CDDP-R and T24 CDDP-R cells. In the orthotopic bladder cancer model, systemic LASP1 ASO administration to athymic nude mice delayed tumor progression in T24 CDDP-R cells.
INTRODUCTION AND OBJECTIVES: The immune system is increasingly recognized as both a key player in cancer control and as druggable target. We hypothesized that the immune system impacts pathologic response in patients undergoing cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer though the immune system. METHODS: Whole exome sequencing (WES) was performed on tumor DNA from patients in two independent cohorts who underwent cisplatin-based NAC. The Memorial Sloan Kettering / Dana Farber Cancer Institute (n¼50; 25 responders) and Philadelphia (n¼48; 20 responders) cohorts were treated with gemcitabine / cisplatin or methotrexate / vinblastine / doxorubicin / cisplatin. Mutation analysis was performed using standard analytical pipelines. Macrohistocompatibility complex (MHC)-restricted neoantigens were identified with netMHCpan and PolySolver. High affinity neoantigens were defined to have 500 nM binding affinity (K d ). Pathologic response was defined as ypTis cystectomy specimen. CIBERSORT was used to infer immune cell infiltrate based on DASL Illumina microarray expression profiles (n¼41; 17 responders).
RESULTS: Chemoresponders had >twice as many putative neoantigens as nonresponders (471 vs 207 neoantigens respectively; p¼1x10 -6 , Wilcoxon). This relationship maintained significance when neoantigens were limited to K d 100 nM or 50 nM, and when chemoresponse was defined as ypT0-only, or ypT1. ERCC2 loss-offunction mutations were 36% sensitive in identifying chemoresponders but 96% specific. Above-median neoantigen burden was 81% sensitive in identifying chemoresponders and 78% specific. CD8 + cells were enriched in responders (13.5% vs 8.4% of infiltrate; p<0.008, t-test) as were activated NK cells (15.5% vs 12.7%; p¼0.05). In 28 samples where WES and CIBERSORT data was available, the neoantigen burden was correlated to the CD8 + infiltrate value (R 2 ¼0.33, Pearson).
CONCLUSIONS: Neoantigen burden and CD8 + infiltrate correlate strongly with chemoresponse. Neoantigen burden and CD8 + infiltrate are directly proportional. NAC may therefore exert known tumor cell autonomous effects and an extrinsic effect involving the immune system via neoantigens. Anti-neoantigen responses have been shown to impact immune checkpoint responses and a similar mechanism may mediate cytotoxic chemoresponse. Experiments are underway to directly and functionally characterize the effect of the immune system in chemoresponse. 
INTRODUCTION AND OBJECTIVES:
It is known that patients with the same TNM stage can have different clinical outcomes. There is increasing evidence that cytotoxic T lymphocytes distribution between the tumour core (CT) and invasive margin (IM) correlates with disease free survival (DFS) and overall survival (OS) in other malignancies. The effect of a particular immune response is determined by the balance between the various T-cell subtypes involved, mainly the cytotoxic lymphocytes CD8+ and CD3+. In this sense, the Immunoscore, a new approach to the classification of cancer using the number, type and distribution of immune cells has been developed. Our objective was to evaluate the the prognostic impact of lymphocyte distribution in bladder cancer.
METHODS: Hematoxylin and eosin (H&E) stained slides of cystectomy permanent sections with tumour involvement and identifiable invasive margin were selected and stained for CD8+ lymphocytes. Three non-contiguous areas of highest lymphocyte density were selected from both CT and IM. The number of CD8+ lymphocytes were calculated using Aperio image analysis software. Nonparametric (WilcoxoneManneWhitney) test was used to identify markers with a significantly different expression among patient groups. KaplaneMeier curves were used to visualize differences between DFS and OS.
RESULTS: 67 patients who had cystectomy for T1-T4 bladder cancer were included in the study. High concentration of CD8+ lymphocytes in the tumour margin is associated with better DFS (P¼0.005) and OS (P¼0.03). Similar results were found for CD3+ lymphocytes with regards to DFS (P¼0.05) but results did not meet statistical significance for OS (P¼0.07). A higher Immunoscore is also associated with better DFS (P¼0.04). After controlling for T stage, lymphovascular invasion, and peri-operative chemotherapy, higher levels of CD8+ in the invasive margin was independently associated with better outcomes (DFS: HR 0.26, 95% CI 0.10-0.68, P¼0.006, OS: HR 0.031, 95% CI 0.10-0.97, P¼0.04) CONCLUSIONS: The host's own immune system plays a valuable role in cancer progression. Our data suggests that a strong immune response against the tumour, as demonstrated by high concentration of CD8+ lymphocytes in the tumour margin, is independently associated with better prognosis. In the future, we plan on evaluating markers other than CD3+ that can be used with CD8+ for more accurate Immunoscore determination for bladder cancer. and pelvis remains the main site of local recurrence. We sought to investigate whether aggressiveness of bladder cancer correlated with washings in the pelvis & pneumo-peritoneum at different stages of robot-assisted radical cystectomy (RARC).
METHODS: 20 patients who underwent RARC were prospectively enrolled in the study. 6 samples were collected from each patient: Intra-vesical washing prior to RARC (BW), followed by a series of 3 pelvic irrigations; before RARC (Wash 1), after RARC (Wash 2) and after pelvic lymph node dissection (PLND) (Wash 3). Leftover suction fluid from the whole procedure was also collected (Wash 4). A specialized filter from surgical smoke evacuation device was used to trap any cells circulating in the pneumoperitoneum. Each sample was examined for cytology and the presence of bladder cancer-related markers (CDK1, HOXA13, MDK, IGFBP3). Results were correlated with clinical outcomes.
RESULTS: 18 patients were included in the study (2 excluded for concomitant malignancies). MDK had the highest detection rate in the study. CDK1 had the lowest detection rate among the four markers and was only detected in 1 intra-vesical wash (pT1). There was no difference in the detection rate of the mRNA markers between muscle invasive and non-invasive tumors. However, mRNA in the pelvic irrigation and suction fluids were only detected in invasive (78%) and metastatic (100%) stages. Cytology results showed atypical cells in 4 patients (1 -Wash 3, 3 -Wash 4). After a median follow-up of 7 months, 2 patients developed distant recurrences (ypT0/N1, pT4a/N2) and 1 patient had pelvic recurrence (T4b/N0). No transmission of tumor cells was seen in the pneumo-peritoneum insufflation CO2 used during RARC.
CONCLUSIONS: This simple novel methodology was able to provide valuable information regarding possible pelvic dissemination. Patients with more advanced disease after RARC may have higher odds of bladder cancer dissemination in the pelvis during RARC. 
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INTRODUCTION AND OBJECTIVES: Traditional cigarette
smoking is a well-established cause of bladder cancer. E-cigarette use is gaining popularity in part due to the perception it represents a safer alternative to smoking. Initial studies have shown the composition of e-cigarette liquids to be complex and may contain nitrosamines, formaldehyde, acrolein, metals, and acetaldehyde many of which are known bladder carcinogens. We compared the urine of e-cigarette users to non-smoking, non e-cigarette using controls by liquid chromactographymass spectrometry (LC-MS) for known bladder carcinogens.
METHODS: Urine samples were collected from 13 e-cigarette users and 10 non-smoking, non e-cigarette using controls. Samples were acidified, hydrolyzed, extracted, dried and resuspended for LC-MS analysis. Five molecules known to be bladder carcinogens that are either present in traditional cigarettes or common solvents believed to be used in some e-cigarette formulations were targeted for analysis. These included benz(a)anthracene, benzo(a)pyrene, 1-hydroxypyrene, o-toluidine and 2-naphthylamine (limit of detection 10-100 ng/ml).
RESULTS: Subjects were predominantly male with a mean age of 39.4 years. All subjects had abstained completely by self-report from traditional cigarettes for at least 6 months prior to specimen collection ( Table 1) . Analysis of e-cigarette user urine was positive for two of the carcinogenic compounds, o-toluidine and 2-naphthylamine (limits of detection 100 ng/ml and 10 ng/ml respectively), in 12/13 e-cigarette users but none of the ten controls (Fischer's exact ¼ 0.0069). The other 3 tested urinary carcinogens were not identified.
CONCLUSIONS: E-cigarettes are historically unregulated with a wide variety of formulations. Previous studies have identified nitrosamines in low levels in e-cigarette formulations as well as a variety of solvents such as formaldehyde. Twelve of the 13 subjects studied had carcinogenic 2-naphtylamine and 0-toluidine present. Many of these subjects (9/13) were long term nonsmokers (>12 months). Further study is needed to clarify the safety profile of e-cigarettes and their contribution to the development of bladder cancer given the greater concentration of carcinogenic nitrosamines in the urine of e-cigarette users in this pilot study. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1179
